NewGenIvf Group Ltd(NIVF)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $23.7M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NIVF Stock Analysis & AI Quality Score
AI stock analysis and institutional research for NewGenIvf Group Ltd (NIVF), a Healthcare sector company. NIVF is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $23.7m in revenue. Based on the latest XBRL financial filings (FY 2025), NewGenIvf Group Ltd reports quarterly revenue of $4.7M, net income of $9.9M, free cash flow of $-11.1M. Top institutional holders of NIVF by reported 13-F value include Polar Asset Management Partners, Clear Street Group, MMCAP International SPC, based on the most recent SEC filings. NIVF trades on the Nasdaq exchange and files with the SEC under CIK 1981662. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NIVF daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NewGenIvf Group Ltd directly from SEC EDGAR.
Revenue
FY 2025
$4.7M
Net Income
FY 2025
$9.9M
Free Cash Flow
FY 2025
$-11.1M
AI Insight: NIVF Financial Trends
Equity swung from negative $1M to positive $27M in two years, signaling capital restructuring or fresh fundraising, but revenue and profitability metrics remain absent.
• Shareholders' equity recovered from -$1M (Q4 2024) to $27M (Q4 2025), a $28M swing in one year.
⚠ Revenue, net income, operating income, and operating cash flow all unpublished—cannot assess underlying operational performance or sustainability.
⚠ Equity was negative in Q4 2024, indicating prior balance-sheet distress; recovery method and drivers unclear.
AI Insight: NIVF Ratio Trends
Insufficient data: all ratio fields are blank across Q4 2023–Q4 2025, preventing trend analysis.
• No operational, profitability, or return metrics available for analysis across the three-year period.
⚠ Complete absence of reported financials suggests data gaps, delisting, or non-reporting status requiring clarification.
Get alerted when NIVF's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NewGenIvf Group Ltd including:
Top Institutional Holders of NIVF
Polar Asset Management Partners Inc.
$10.8K637,966 shClear Street Group Inc.
$5.5K389,370 shMMCAP International Inc. SPC
$5.3K375,000 shD. E. Shaw & Co., Inc.
$3.3K168,750 shWalleye Trading LLC
$2.3K161,871 shRIVERNORTH CAPITAL MANAGEMENT, LLC
$2.0K143,997 shTORONTO DOMINION BANK
$700.0050,000 shCITADEL ADVISORS LLC
$581.0029,346 shPERISCOPE CAPITAL INC.
$560.0040,000 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$375.0018,925 sh
| Fund | Value | Shares |
|---|---|---|
| Polar Asset Management Partners Inc. | $10.8K | 637,966 |
| Clear Street Group Inc. | $5.5K | 389,370 |
| MMCAP International Inc. SPC | $5.3K | 375,000 |
| D. E. Shaw & Co., Inc. | $3.3K | 168,750 |
| Walleye Trading LLC | $2.3K | 161,871 |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | $2.0K | 143,997 |
| TORONTO DOMINION BANK | $700.00 | 50,000 |
| CITADEL ADVISORS LLC | $581.00 | 29,346 |
| PERISCOPE CAPITAL INC. | $560.00 | 40,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $375.00 | 18,925 |
More Healthcare Companies
View all Healthcare →Put NIVF on your watchlist
Track score changes the day NewGenIvf Group Ltd files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NIVF a good stock to buy?
13F Pro's AI-powered analysis of NewGenIvf Group Ltd (NIVF) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NIVF are available on the NIVF stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NIVF?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NIVF. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NewGenIvf Group Ltd's investment landscape.